Anterogen.Co.Ltd Valuation

Is A065660 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A065660 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A065660's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A065660's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A065660?

Key metric: As A065660 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A065660. This is calculated by dividing A065660's market cap by their current revenue.
What is A065660's PS Ratio?
PS Ratio	23.4x
Sales	₩6.66b
Market Cap	₩144.61b

A065660 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	15.7x
Enterprise Value/EBITDA	-33.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A065660's PS Ratio compare to its peers?

The above table shows the PS ratio for A065660 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	21.7x
A191420 TegoScience	17.3x	n/a	₩120.3b
A011000 GeneOne Life Science	4.3x	n/a	₩174.8b
A217330 Cytogen	48.7x	n/a	₩169.6b
A182400 NKMAX	16.5x	n/a	₩172.7b
A065660 Anterogen.Co.Ltd	23.4x	n/a	₩144.6b

Price-To-Sales vs Peers: A065660 is expensive based on its Price-To-Sales Ratio (23.4x) compared to the peer average (21.7x).

Price to Sales Ratio vs Industry

How does A065660's PS Ratio compare vs other companies in the KR Biotechs Industry?

27 Companies	Price / Sales	Estimated Growth	Market Cap
A006280 GC Biopharma	0.9x	8.8%	US$1.07b
A096530 Seegene	2.6x	14.5%	US$735.96m
A086900 Medy-Tox	3.6x	12.5%	US$634.98m
A005250 Green Cross Holdings	0.3x	n/a	US$462.72m

27 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A065660 is expensive based on its Price-To-Sales Ratio (23.4x) compared to the KR Biotechs industry average (8.7x).

Price to Sales Ratio vs Fair Ratio

What is A065660's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A065660 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	23.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A065660's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩282,000.00

6.8%

76.9%

J2KBIO

₩52.9b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,210.00

-5.0%

n/a

Medy-Tox

₩883.1b

Operates as a biopharmaceutical company in South Korea.

A086900

₩132,000.00

3.4%

-38.6%